Current Problems in Cancer
Volume 31, Issue 3 , Pages 211-225 , May 2007

Prostate Cancer and Race

  • Otis W. Brawley, MD

      Affiliations

    • Department of Hematology and Oncology, Emory School of Medicine, Department of Epidemiology, Rollins School of Public Health, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    • Corresponding Author InformationAddress correspondence to Otis W. Brawley, MD, Emory Clinic C Bldg, Atlanta, GA 30322, USA.
    • ,
  • Ashesh B. Jani, MD

      Affiliations

    • Department of Radiation Oncology, Emory School of Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    • ,
  • Veraj Master, MD, PhD

      Affiliations

    • Department of Urology, Emory School of Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA

References 

  1. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001;23:181–186
  2. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2002.
  3. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998;90:1230–1231
  4. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring. J Natl Cancer Inst. 2005;97:1407–1427
  5. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914–923
  6. Boyle P. Screening for prostate cancer: have you had your cholesterol measured?. BJU Int. 2003;92:191–199
  7. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134–1141
  8. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149
  9. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J. 2002;325:740
  10. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990
  11. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998;90:1230–1231
  12. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst. 2002;94:958–960
  13. Ingles SA, Ross RK, Yu MC, Irvine RA, La PG, Haile RW, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997;89:166–170
  14. Liu L, Cozen W, Bernstein L, Ross RK, Deapen D. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst. 2001;93:705–709
  15. Steenland K, Rodriguez C, Mondul A, Calle EE, Thun M. Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control. 2004;15:939–945
  16. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998;16:3101–3104
  17. Roetzheim RG, Pal N, Tennant C, Voti L, Ayanian JZ, Schwabe A, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999;91:1409–1415
  18. Polednak AP. Stage at diagnosis of prostate cancer in Connecticut by poverty and race. Ethn Dis. 1997;7:215–220
  19. Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003;14:761–766
  20. Pan CC, Lee JS, Chan JL, Sandler HM, Underwood W, McLaughlin PW. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates. Int J Radiat Oncol Biol Phys. 2003;57:1292–1296
  21. Brown ML, Potosky AL. The presidential effect: the public health response to media coverage about Ronald Reagan’s colon cancer episode. Public Opin Q. 1990;54:317–329
  22. Satia-Abouta J, Patterson RE, Schiller RN, Kristal AR. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med. 2002;34:493–501
  23. Tarman GJ, Kane CJ, Moul JW, Thrasher JB, Foley JP, Wilhite D, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000;56:1016–1020
  24. Gordon NH. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol. 1995;142:796–803
  25. Harlan LC, Coates RJ, Block G, Greenberg RS, Ershow A, Forman M, et al. Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology. 1993;4:25–31
  26. Brewster DH, Thomson CS, Hole DJ, Black RJ, Stroner PL, Gillis CR. Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. Br Med J. 2001;322:830–831
  27. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439–445
  28. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001;58:723–728
  29. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439–443
  30. Sakr WA, Billis A, Ekman P, Wilt T, Bostwick DG. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol Suppl. 2000;11–18
  31. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 2005;48:739–744
  32. Sanchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003;54:238–247
  33. Haenszel W, Kurihara M. Studies of Japanese migrants (I. Mortality from cancer and other diseases among Japanese in the United States). J Natl Cancer Inst. 1968;40:43–68
  34. Haenszel W. Studies of migrant populations. Am J Public Health. 1985;75:225–226
  35. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998;58:4497–4504
  36. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  37. Brawley OW, Ford LG, Thompson I, et al. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994;3:177–182
  38. Ross RK. The role of molecular genetics in chemoprevention studies of prostate cancer. IARC Sci Publ. 2001;154:207–213
  39. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005;23:246–253
  40. Kidd LC, Paltoo DN, Wang S, Chen W, Akereyeni F, Isaacs W, et al. Sequence variation within the 5′ regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate. 2005;64:272–282
  41. Thompson IM, Basler JA, Leach R, Troyer D, Klein E, Brawley O. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer. Urol Oncol. 2003;21:73–78
  42. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55:1937–1940
  43. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000;92:2009–2017
  44. Kittles RA, Young D, Weinrich S, Hudson J, Argyropoulos G, Ukoli F, et al. Extent of linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. Hum Genet. 2001;109:253–261
  45. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 1999;53:378–380
  46. Panz VR, Joffe BI, Spitz I, Lindenberg T, Farkas A, Haffejee M. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine. 2001;15:213–216
  47. Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002;20:3599–3604
  48. Powell IJ, Land SJ, Dey J, Heilbrun LK, Hughes MR, Sakr W, et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 2005;103:528–537
  49. Morris CR, Snipes KP, Schlag R, Wright WE. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control. 1999;10:503–511
  50. Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, et al. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003;62:1035–1039
  51. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13:93–100
  52. Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337–1348
  53. Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:1864–1871
  54. Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19:146–155
  55. Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis W, Moul J, et al. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care. 2004;42:239–250
  56. Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health. 2003;93:1753–1759
  57. Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95:1702–1710
  58. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol. 2000;151:409–416
  59. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. J Am Med Assoc. 2002;287:2106–2113
  60. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334–357
  61. Young CD, Lewis P, Weinberg V, Lee TT, Coleman CW, Roach M. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy. Semin Urol Oncol. 2000;18:121–126
  62. Hart KB, Wood DP, Tekyi-Mensah S, Porter AT, Pontes JE, Forman JD. The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy. Int J Radiat Oncol Biol Phys. 1999;45:1235–1238
  63. Roach M, Krall J, Keller JW, Perez CA, Sause WT, Doggett RL, et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys. 1992;24:441–449
  64. Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000;56:87–91
  65. Fowler JE, Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996;156:1714–1718
  66. Iselin CE, Box JW, Vollmer RT, Layfield LJ, Robertson JE, Paulson DF. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer. 1998;83:2353–2360
  67. McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway MS, Sharifi R, Block NL, et al. The Casodex Combination Study Group Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. Prostate. 1999;40:218–224
  68. Fowler JE, Bigler SA, Renfroe DL, Dabagia MD. Prostate specific antigen in black and white men after. J Urol. 1997;158:150–154
  69. Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  70. Austin JP, Aziz H, Potters L, Thelmo W, Chen P, Choi K, et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol. 1990;13:465–469
  71. Kim JA, Kuban DA, el-Mahdi AM, Schellhammer PF. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology. 1995;194:545–549
  72. Austin JP, Convery K. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation. Am J Clin Oncol. 1993;16:140–145
  73. Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology. 2002;225:420–426
  74. Brawley OW. Population categorization and cancer statistics. Cancer Metastasis Rev. 2003;22:11–19

 Supported by grant number P60MD000525 from the National Center for Minority Health and Health Disparities and funding from the Georgia Cancer Coalition.

PII: S0147-0272(07)00007-4

doi: 10.1016/j.currproblcancer.2007.01.006

Current Problems in Cancer
Volume 31, Issue 3 , Pages 211-225 , May 2007

Article Tools

* Image Usage & Resolution